Handelsavisen
prelaunch
Companies ›Healthcare ›504A.T
50
504A.T — Tokyo Stock Exchange Pharmaceuticals

Innovacell Inc

¥519,00
Open in Charts → Attach watcher ⌖
— —
JPY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
23,4B JPY
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
—
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Innovacell Inc is a biotechnology company focused on pharmaceuticals and medical research, developing and commercializing therapeutic products for healthcare applications.

Business. Innovacell Inc is a pharmaceutical company engaged in the development and sale of healthcare products. The firm is headquartered in Japan and primarily listed on the Tokyo Stock Exchange under the ticker symbol 504A.T. Specific details regarding operating segments and geographic revenue mix are not disclosed.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability
—
not yet wired
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 504A.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 504A.T. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Innovacell Inc is a pharmaceutical company engaged in the development and sale of healthcare products. The firm is headquartered in Japan and primarily listed on the Tokyo Stock Exchange under the ticker symbol 504A.T. Specific details regarding operating segments and geographic revenue mix are not disclosed.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    Innovacell Inc has a market capitalization of ¥29.35 billion, with a market price of ¥650 per share, and no dilution risk based on the current share count of 45.15 million shares outstanding, both basic and diluted. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

    Profitability and return metrics are not available for Innovacell Inc, as no financial ratios or industry benchmarks have been provided in the input data. This limits the ability to compare the company’s performance against industry peers or assess its operational efficiency.

    Innovacell Inc operates in the biotechnology segment of the healthcare industry, with no disclosed geographic revenue breakdown. The company’s exposure to specific markets or regions is not quantified in the available data, making it difficult to assess the risk of geographic concentration.

    Growth trajectory data is not available for Innovacell Inc, as no revenue history or outlook figures have been provided in the input data. This limits the ability to assess the company’s future performance or market expansion potential.

    Risk factors for Innovacell Inc include the inability to assess liquidity risk due to missing balance-sheet data and the absence of going-concern language in source documents. Additionally, the company has no near-term dilution risk, as the basic and diluted share counts are identical.

    Recent events or filings for Innovacell Inc are not disclosed in the input data, limiting the ability to assess any material developments or strategic shifts in the company’s operations.

    Key takeaways
    • Innovacell Inc is a biotechnology company with a market capitalization of ¥29.35 billion and no dilution risk.
    • Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language in source documents.
    • Profitability and return metrics are not available, limiting the ability to compare the company’s performance against industry peers.
    • Geographic revenue exposure and growth trajectory data are not disclosed, making it difficult to assess market concentration and expansion potential.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation FY

    Market price
    ¥519,00
    Market cap
    ¥29.35B
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    —
    Net cashⓘ
    —
    Current ratioⓘ
    —
    Debt / equityⓘ
    —
    ROAⓘ
    —
    ROEⓘ
    —
    Cash conversionⓘ
    —
    CapEx / revenueⓘ
    —
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    No cohort benchmark data available for this issuer yet.

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • Innovacell Inc Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    504A.TCanonical
    Tokyo Stock Exchange · JPY

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage